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Restless Legs Syndrome (RLS) is often and successfully treated with dopamine receptor
agonists that target the inhibitory D3 receptor subtype, however there is no clinical
evidence of a D3 receptor dysfunction in RLS patients. In contrast, genome-wide
association studies in RLS patients have established that a mutation of theMEIS1 gene is
associated with an increased risk in developing RLS, but the effect ofMEIS1 dysfunction
on sensorimotor function remain unknown. Mouse models for a dysfunctional D3
receptor (D3KO) and Meis1 (Meis1KO) were developed independently, and each animal
expresses some features associated with RLS in the clinic, but they have not been
compared in their responsiveness to treatment options used in the clinic. We here confirm
that D3KO and Meis1KO animals show increased locomotor activities, but that only
D3KO show an increased sensory excitability to thermal stimuli. Next we compared
the effects of dopaminergics and opioids in both animal models, and we assessed D1
and D3 dopamine receptor expression in the spinal cord, the gateway for sensorimotor
processing. We found that Meis1KO share most of the tested behavioral properties with
their wild type (WT) controls, including the modulation of the thermal pain withdrawal
reflex by morphine, L-DOPA and D3 receptor (D3R) agonists and antagonists. However,
Meis1KO and D3KOwere behaviorally more similar to each other than toWTwhen tested
with D1 receptor (D1R) agonists and antagonists. Subsequent Western blot analyses of
D1R and D3R protein expression in the spinal cord revealed a significant increase in D1R
but not D3R expression in Meis1KO and D3KO over WT controls. As the D3R is mostly
present in the dorsal spinal cord where it has been shown tomodulate sensory pathways,
while activation of the D1Rs can activate motoneurons in the ventral spinal cord, we
speculate that D3KO and Meis1KO represent two complementary animal models for
RLS, in which the mechanisms of sensory (D3R-mediated) and motor (D1R-mediated)
dysfunctions can be differentially explored.
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INTRODUCTION
Background on RLS
Restless Legs Syndrome (RLS) is a highly prevalent (5–10%
of the population, Ghorayeb and Tison, 2010; Earley et al.,
2011), but also underappreciated aging-associated neurological
sensorimotor disorder that severely disrupts sleep and affects
quality of life. First described in 1685 (Willis, 1685) and clinically
confirmed in the mid-twentieth century (Ekbom, 1944, 1945,
1960), RLS is a clinical disorder in which overlapping genetic
risk factors may play a role in the emergence of the symptoms
(Trenkwalder et al., 2016). Genome-wide association studies in
RLS patients have established several chromosome loci associated
with RLS, notably MEIS1 and BTBD9 (Stefansson et al., 2007;
Winkelmann et al., 2007), of which a pointmutation in theMEIS1
gene has the highest odd ratios with RLS (Winkelmann, 2008;
Schormair et al., 2011, 2017; Winkelmann et al., 2011). Meis1
plays a role in the early development of the nervous system
(Spieler et al., 2014; Marcos et al., 2015), and is essential to specify
cell fates and differentiation patterns along the proximodistal
axis of the limbs (Mercader et al., 1999, 2009). Intriguingly, a
dysfunction of the MEIS1 homolog in C. elegans is associated
with an altered projection phenotype of dopamine neurons
(M. Aschner, Albert Einstein College of Medicine, personal
communication), suggesting a possible interaction between
MEIS1 and dopamine (DA) function.
RLS is often and successfully treated with DA receptor
agonists that target the inhibitory D2-like receptor subtype, in
particular D3 (Stiasny et al., 2000; Ferri et al., 2010; Manconi
et al., 2011a; Garcia-Borreguero et al., 2016), and it has been
suggested that a dysfunction of the descending A11 DA system
in the hypothalamus may be involved in RLS by predominantly
affecting the D3R system (Clemens et al., 2006; Lanza et al.,
2017). There exist three DA receptors that mediate inhibitory
actions via Gi-coupled pathways (D2, D3, and D4), and the D3R
subtype has a very high affinity to DA (Robinson et al., 1994;
Cote and Kuzhikandathil, 2014). Yet despite the efficacy of the
D3R compounds in treating RLS symptoms, there is no clinical
evidence of A11 dysfunction in patients (Earley et al., 2009).
However, a dysfunction of the DA system has been linked to
altered iron homeostasis or iron-deficient diet (Dowling et al.,
2011; Klinker et al., 2011; Dauvilliers and Winkelmann, 2013;
Earley et al., 2014).
Animal Models of RLS
Mouse models for a dysfunctional D3 receptor (D3KO) and
Meis1 (Meis1KO) were developed independently (Accili et al.,
1996), and each animal expresses some features associated with
RLS in the clinic. Both D3KO and Meis1KO express increased
locomotor activity (Accili et al., 1996; Salminen et al., 2017), but
only D3KO show an increased sensory excitability both in the
isolated spinal cord (Clemens and Hochman, 2004) and in vivo
(Keeler et al., 2012). The thermal pain withdrawal reflex depends
on spinal cord circuits that can be recruited experimentally to
assess compromised function of the underlying neural networks,
both with the spinal cord and extending into the periphery.
The previously reported increased excitability of the D3KO
mouse to thermal stimuli suggests a possible role of C-fiber
mediated pathways that convey altered sensations from deep
within the muscle tissue (Clemens et al., 2006; Keeler et al., 2012).
Further, as recent data suggest that the inhibitory D3 receptor
can form functional heteromeric dimers with the excitatory D1
receptor (Marcellino et al., 2008), it is conceivable that the
increased excitability observed in D3KO may be the result of
an increased expression of the excitatory dopamine D1 receptor
(D1R) (Brewer et al., 2014).
We here compared the effects of dopaminergic treatment
on spinal reflexes as a tool to assess sensorimotor function
(Eccles and Lundberg, 1959; Nielsen, 2004; Barriere et al.,
2005) in Meis1KO and D3KO animal models, and we assessed
D1R and D3R expressions the spinal cord, the gateway
for sensorimotor processing. We found that Meis1KO share
most of the tested behavioral properties with their wild type
(WT) controls, including the modulation of the thermal pain
withdrawal reflex by morphine, L-DOPA and D3 receptor (D3R)
agonists and antagonists. However, Meis1KO and D3KO also
shared behavioral similarities when tested with D1 receptor
(D1R) agonists and antagonists, while the matching WTs were
unresponsive to these drugs. Subsequent Western blot analyses
of D1R and D3R protein expression in the spinal cord revealed
a significant increase in D1R expression in Meis1KO and D3KO
over theWT controls, while D3R expression was not significantly
different across all 3 groups. Our data show that changes
in spinal D1R expression and behavioral responses to D1R
compounds are similar between Meis1KO and D3KO, while the
increased sensitivity at baseline is present only in D3KO. We
provide a model that separates D3KO and Meis1KO into two




All experimental procedures were approved by the Institutional
Animal Care and Use Committees at East Carolina University
and University of Florida, and were fully compliant with the
National Institutes of Health guide for the care and use of
Laboratory animals (NIH Publications No. 80-23). All efforts
were made to minimize the number of animals used, and
a total of 55 male mice (age range ∼9–12 months) were
tested in this study. Behavioral testing was performed on Meis1
heterozygous knockout mice (Meis1+/1, Meis1KO, n= 15) and
their appropriate wild-type (WT) controls (C57BL/6J, n = 12),
dopamine D3 receptor knockout mice (D3KO; strain B6.129S4-
Drd3tm1dac/J (stock # 002958, Jackson Laboratory, Bar Harbor,
ME), n = 13) and their appropriate WT controls (C57BL/6J,
n = 15) (Clemens and Hochman, 2004; Brewer et al., 2014).
Meis1 loxP mice were from Drs. Copeland and Sadek (Kocabas
et al., 2012), and Meis1+/1 were generated by crossing Meis1
loxP with Emx1-cre mice (Guo et al., 2000). Emx1 expresses in
testis germ cells, so that when germ cells contain both Emx1-
cre and Meis1 loxP, cre-mediated recombination occurs and
leads to a deletion of the loxP-flanked sequence. Male mice
heterozygous for both Meis1 loxP and Emx1-cre were then bred
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with WT female mice. The deletion of Meis1 gene occurred
during the development and Meis1+/1 mice were derived.
Finally, Meis1+/1 mice were crossed with WT mice to generate
experimental mice. Animals were housed with free access to food,
water, and enrichments under a 12-h light/dark cycle at room
temperature.
Behavioral Assessments–Hargreaves
Behavioral testing procedures have been described in detail
recently (Keeler et al., 2012; Brewer et al., 2014). Thermal
withdrawal latencies (Hargreaves’ method) were obtained in each
cohort by using the IITC plantar analgesia meter (IITC Series 8,
IITC Inc., Woodland Hills, CA). Experiments were performed
between 9 am and 1 pm, to minimize the circadian variation. The
week before testing started, animals were acclimated on 3–4 days
to the experimental room and the Hargreave’s system, by placing
them individually into the Plexiglas cubicles for an average of 2 h.
In week 1 of the testing period, we tested the effects of vehicle
injections (0.9% NaCl, i.p., ∼90–120 µl per animal). Animals
were tested 5 times per session, with resting periods for each
individual animal between tests of 5–10min. Stimulation cut-off
for each test was set to 30 s test duration, to prevent the possibility
of a heat-induced injury. Once initiated, recording sessions for
all 5 trials lasted no longer than 60–90min for all animals tested
that day. After vehicle assessments, we subsequently compared
all drug effects (i.p. injections, injection volumes matching the
vehicle volumes) against the data obtained after the respective
vehicle injections in each animal cohort. We started the tests 1 h
after vehicle or drug injections. Each drug test was separated from
the next drug treatment by an at least 3-day recovery period,
to minimize any potential drug interactions possibly skewing
the latency measurements. After ∼5–6 weeks, we again tested
the responses to vehicle injections in two cohorts and found no




Spontaneous locomotor activities were recorded for Meis1KO
and their WT controls with a VersaMax Legacy open field
apparatus connected to a computerized Digiscan System
(Accuscan Instruments, Inc. OH), and for D3KO and
their controls with a TSE LabMaster System (TSE Systems,
Chesterfield, MO). Infrared sensors were used to record
ambulatory activity in the X-Y plane). Counts across all these
axes were summed to give total ambulatory activity. Meis1KO
and their WT controls were monitored for 7 days. Only the data
from the last 4 days were pooled and analyzed. For D3KO and
their controls, after 2 days of acclimation, data were collected for
2 consecutive days to calculate locomotor activity.
Compounds Tested
We tested the effects of levodopa (L-DOPA, 10 mg/kg, Acros
Organics, Geel, Belgium), the D3 receptor agonist, pramipexole
(0.5 mg/kg, ApexBio Technology LLC, Houston, TX), the D3
receptor antagonist, SB277011-A (10 mg/kg, Abcam Cambridge,
MA), the D1 agonist, SKF 38393 (10 mg/kg, Tocris, Ellisville,
MO), the D1 receptor antagonist, SCH 39166 (5 mg/kg,
Tocris, Ellisville, MO), and morphine (morphine sulfate salt
pentahydrate, 2 mg/kg, Sigma-Aldrich St. Louis, MO). Drug
concentrations were chosen based on previous publications by
others and us (Acquas and Di Chiara, 1999; Williams et al., 2006;
Brewer et al., 2014; Solís et al., 2015; Dinkins et al., 2017)
Tissue Harvesting and Protein Isolation
Mice were deeply anesthetized with isoflurane and decapitated
before spinal cords were dissected out, immediately placed
in RNAlater (Thermo Fisher Scientific, Waltham, MA), and
stored at −20◦C until use. Spinal cords were homogenized in
1ml of RIPA buffer with protease and phosphatase inhibitors
(0.12 ml/ml RIPA buffer, Sigma-Aldrich #P2714 and 0.012
ml/ml of RIPA buffer, Sigma-Aldrich #P5726 St. Louis, MO,
respectively). The homogenized spinal cords were centrifuged
(13,000 rpm, 4◦C, 15min), and supernatants were aliquoted
and stored individually at −80◦C. Following homogenization,
standard protein concentrations were established with a Bradford
protein assay (Quickstart Bradford reagent, Bio-Rad #500205),
and plates were read on an EpochMicroplate Spectrophotometer
(BioTek, Winooski, VT) at 595 nm using the Gen5.1 software
package (BioTek, Winooski, VT).
Western Blot
For Western blots, 30 µg of each lumbar spinal cord protein
samples were denatured using 2x Laemmli buffer containing
5% β-mercaptoethanol and 1% SDS at 95◦C for 10min and





Gel (#5678045, Bio-Rad, Hercules, CA) and run ∼45min at
200V. The proteins were transferred to a low fluorescent PVDF
membrane using Trans-Blot R© Turbo
TM
RTA Midi LF PVDF
Transfer Kit (#170-4275, Bio-Rad, Hercules, CA). Membranes
were probed with the primary antibodies and with secondary
antibodies (LI-COR, Lincoln, NE) by the iBind
TM
Flex Western
Device (SLF2000, Thermo Fisher, Waltham, MA) based on
sequential Lateral Flow (SLF) technology using iBind
TM
Flex
Fluorescent Detection (FD) Solution Kit (SLF 2019, Thermo
Fisher, Waltham, MA). Membranes were imaged with an
Odyssey imaging system (Odyssey Clx, LI-COR, Lincoln, NE).
Antibodies
The primary antibodies used for Western blot to detect receptor-
specific protein expression were: anti-dopamine receptor D1
(Abcam 78021, 1:500 Cambridge, MA) and anti-dopamine
receptor D3 (Abcam 42114, 1:1,000 Cambridge, MA). The
secondary antibodies used were goat anti-rabbit 680RD (925-
68071, 1:4,000, LI-COR Biosciences, Lincoln, NE) and goat anti-
mouse 680RD (925-68070, 1:4,000, LI-COR Biosciences, Lincoln,
NE).
Statistical Analysis
Following the experiments, behavioral data were transferred
and stored in Excel format, then analyzed and plotted
offline with SigmaPlot (Version 11, SPSS Science, San Jose,
California). For statistical comparisons, we employed parametric
or non-parametric comparisons as appropriate when comparing
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multiple groups (One-Way ANOVA, RM ANOVA, or ANOVA
on Ranks) with appropriate post-hoc comparisons (Holms-Sidak,
Dunn’s); t-tests or paired t-tests were used for comparison
between two sets of data (treatment against respective control
vehicle treatment only). Significance levels were set at p <
0.05. For Western blot analysis, images were analyzed with
ImageStudio and ImageJ (1.50i National Institutes of Health,
USA) and statistical analyses were performed with SigmaPlot
11.0.
RESULTS
Thermal Pain Withdrawal Latencies Under
Baseline Conditions
We first tested and compared pain withdrawal latency responses
in Meis1KO and D3KO lines under baseline conditions (after
sham injection, i.p., 0.9% NaCl, 100 µl/30 g), and compared
them to their respective controls. Meis1KO and their respective
controls were tested as two independent cohorts. In cohort
1 the average WT latency was 10.2 ± 1.1 s, while Meis1KO
latencies were 10.2 ± 0.5 s (p = 0.97, n = 7 each, power:
0.05). In cohort 2 (tested about 1 year later) the average WT
latency was 6.6 ± 0.4 s, while Meis1KO latencies were 6.7 ±
0.9 s (p = 0.92, n = 6 [WT] and n = 7 [Meis1KO], power:
0.05). Thus despite the difference between the two Meis1KO
cohorts and their WT controls, there was no effect within
each cohort between WT and knockout. In contrast, individual
withdrawal latencies in D3KO ranged per trial from 4.8 to
11.1 s, (average: 8.5 ± 0.24 s, n = 7) while the latencies of their
respective WTs (WTD3KO) ranged from 5.9 to 13.7 s (average: 6.5
± 0.33 s, n = 7). A t-test comparison revealed that the difference
between WTD3KO and D3KO was significant (p < 0.001, power:
0.99).
To illustrate the effect of the genotype alone on thermal pain
withdrawal reflex latencies, we normalized the WTmeis1 response
to 100% and compared them with the effects in the genetically
modified animals (Figure 1). We found that pain withdrawal
latencies of Meis1KO and their respective controls (WTmeis1)
were not significantly different from each other (WTmeis1: 99.9
± 6.1% S.E. n= 13, Meis1KO: 101± 6.7 % S.E., n= 14, p= 0.97,
t-test, power: 0.5), while those of D3KO were significantly
reduced over their respective WTs (WTD3KO: 99.99 ± 2.8%;
D3KO: 77.3 ± 3.9%, S.E., p < 0.001, t-test, both: n = 7, power:
0.99).
Morphine Modulation of Withdrawal
Latencies
While opioids are commonly used for treating chronic
neuropathic pain, they have also become a treatment of choice
in dopamine agonist-refractory RLS (Trenkwalder et al., 2015;
Gemignani et al., 2016). As we have previously shown that
the D3KO mouse expresses a morphine-tolerant phenotype if
treated with low doses of morphine (Brewer et al., 2014), we
next addressed the question if the Meis1KO mouse follows the
WT or the D3KO phenotype when challenged with morphine
(Figure 2). In Meis1KO cohort 1, WT withdrawal latencies
increased from 6.8 ± 0.45 s to 9.1 ± 1.2 s (n = 6), while
responses of Meis1KO increased from 6.3 ± 1.2 s to 10.1 ±
1.1 s (n = 7). Similarly, in cohort 2, WT withdrawal latencies
increased from 6.5 ± 1.2 s to 9.3 ± 1.9 s (n = 5), while responses
of Meis1KO increased from 6.3 ± 0.6 s to 7.9 ± 1.9 s (n = 7).
After normalization to each WTmeis1 control, the data are as
follows: WTmeis1; Ctrl: 99.3 ± 7.1%; after treatment: 132.5 ±
14.8%, p = 0.08, paired t-test, n = 11, power: 0.83, Figure 2A1;
Meis1KO; Ctrl: 99.2 ± 5.7%; after treatment: 143 ± 16.6%,
p = 0.024, paired t-test, n = 14, power: 0.59, Figure 2A2. For
WTD3KO the raw data were as follows; Ctrl: 8.3 ± 0.3 s; after
treatment: 11.4± 0.6 s (n= 7), while D3KO were not responsive
to 2 mg/kg morphine (Ctrl: 6.6 ± 0.4 s; after treatment: 6.1 ±
0.4 s, n = 7). After normalization to the pre-treatment control,
the data for WTD3KO are: 99.8 ± 2.8%; after treatment: 137.1 ±
7%, p= 0.002, paired t-test, power: 0.99; Figure 2B1. In contrast,
normalized the data for the D3KO are: Ctrl 100.6 ± 5%; after
treatment: 95.1 ± 6.6%, p = 0.62, paired t-test, power: 0.05,
Figure 2B2). Together, these data suggest thatWTmeis1, WTD3KO,
andMeis1KO animals respond similar to morphine, while D3KO
are not affected.
Dopaminergic Modulation of Withdrawal
Latencies
Dopaminergics are the first line of therapy in the treatment of
RLS symptoms, and they can cover a range from L-DOPA to
highly specific D3 receptor agonists. We therefore sought to
first test the effects of L-DOPA on thermal withdrawal latencies
in the different animal strains before testing the effects of the
more selective receptor agonists and antagonists. We found that
treatment with 10 mg/kg L-DOPA did not significantly alter
withdrawal latencies in WT controls, Meis1KO or D3KO (data
not shown).
We next tested the effects of the D3-receptor preferring
agonist, pramipexole (PPX, Figures 3, 4). In WTmeis1, treatment
with PPX (0.5 mg/kg) increased withdrawal latencies from 100.2
± 6.6% to 144.4± 13.7%, (p= 0.008, paired t-test, n= 11, power:
0.81, Figure 3A1; raw data for WTmeis1 cohort 1: Ctrl 6.1± 0.7 s,
PPX 9.6± 1.3 s, n= 6; cohort 2: Ctrl 7.2± 0.5 s; PPX: 8.6± 0.9 s,
n = 5). In Meis1KO, the PPX treatment also led to a significant
increase in withdrawal latencies from 100.1 ± 8.9% to 131.3 ±
12.3% (p = 0.017, paired t-test, n = 14, power: 0.65, Figure 3A2;
raw data for Meis1KO cohort 1: Ctrl 6.7 ± 0.9 s, PPX 9.1 ± 1.2 s,
n= 7; cohort 2: Ctrl 7.2± 0.9 s; PPX: 7.8± 1 s, n= 7). The effect
of PPXwas similar in theWT of the D3KOmice (WTD3KO) to the
effect observed in WTmeis1 and Meis1KO, but it did not alter the
responses in the D3KO. In WTD3KO, withdrawal latencies rose
significantly from 100 ± 6.3% (Ctrl) to 204.8 ± 9% (PPX, p <
0.001, paired t-test, n = 8, power: 1.0, Figure 3B1). In contrast,
PPX did not have any significant effect in D3KO (Ctrl: 100 ±
5.6%, PPX: 108.4 ± 5.6%, p = 0.47, t-test, n = 6, power: 0.5,
Figure 3B2). The raw data were as follows: WTD3KO; Ctrl 6.6 ±
0.5 s, PPX 12.9 ± 1.8 s, n = 8; D3KO; Ctrl 9.3 ± 0.6 s; PPX: 10.1
± 0.8 s, n= 9.
Additionally, treatment with the D3 receptor antagonist, SB
277011, significantly decreased withdrawal latencies in Meis1KO
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FIGURE 1 | Thermal pain withdrawal latencies under vehicle (control) conditions. (A) Normalized representation of data from Meis1KO mice and their respective WT
controls (WTmeis1). WT meis1 latencies (black bar) were similar to those of Meis1KO (gray bar). (B) Normalized representation of data from D3KO animals and
respective WT controls (WT D3KO ). WT D3KO latencies (black bar) were significantly higher than those of the D3KO (gray bar).
but not D3KO (Figure 4). In Meis1KO, withdrawal latencies
dropped from 99.5 ± 6.3% (Ctrl) to 78.5 ± 4.4% (SB277,
p= 0.004, n= 7, paired t-test, power: 0.96, Figure 4A). However,
we did not observe any significant effect in D3KO mice (Ctrl:
99.9 ± 5.3%, SB277: 92.8 ± 3.6%, p = 0.28, n = 6, paired t-test,
power: 0.09, Figure 4B). The raw data were as follows: Meis1KO;
Ctrl 7.2 ± 0.6 s, SB277 5.2 ± 0.2 s, n = 7; D3KO; Ctrl 7.9 ±
0.3 s; SB277: 7.8 ± 0.2 s, n = 6. Overall, treatment with the D3
receptor modulators led to similar effects in WT and Meis1KO
and contrasted those in D3KO.
As recent findings from our lab point to a possible
involvement of the D1 receptor in the face of D3 dysfunction
(Brewer et al., 2014) or prolongedD3R agonist exposure (Dinkins
et al., 2017), we next tested the effects of the D1 receptor agonist,
SKF 38393 (SKF, Figure 5). We found that treatment with SKF
had no significant effect in WTmeis1 animals (Ctrl: 99.9 ± 8.2%;
SKF: 92 ± 6.4%, p = 0.77, paired t-test, n = 5, power: 0.05,
Figure 5A1), while the same treatment led to significant decrease
of withdrawal latencies in Meis1KO (Ctrl: 99.9± 8.2%; SKF: 82.4
± 5.7%, p= 0.001, paired t-test,N = 7, power: 0.98, Figure 5A2).
The raw data were as follows: WTMeis1; Ctrl 6.6 ± 0.3 s, SKF 6.2
± 0.5 s; Meis1KO; Ctrl 6.9± 0.5 s; SKF: 5.4± 0.3 s.
InWTD3KO animals, SKF effects were similar toWTmeis1 (Ctrl:
100.1 ± 6.6%, SKF: 92.2 ± 5.9%, p = 0.37, n = 5, power: 0.051,
Figure 5B1), while the responses in D3KO were similar to those
in Meis1KO (Ctrl: 99.8 ± 3.9%, SKF: 71.6 ± 3.6%, p < 0.001,
n = 6, power: 1.0, Figure 5B2). The raw data were as follows:
WTD3KO; Ctrl 16.8± 1.9 s, SKF 14± 1.2 s; D3KO; Ctrl 8.4± 0.9 s;
SKF: 5.9± 0.8 s. In contrast to theD1 receptor agonist SKF 38393,
the D1 receptor antagonist, SCH 39166, displayed no differential
effects in WT controls, Meis1KO or D3KO animals (WTMeis1
animals: Ctrl: 100.3 ± 7.2%, SCH: 102.3 ± 12%, p = 0.89, paired
t-test, n = 5, power: 0.05, Meis1KO: Ctrl: 100.3 ± 6.9%, SCH:
110.6 ± 11%, p = 0.4, paired t-test, n = 7, power: 0.05; D3KO:
Ctrl: 99.7± 5.5%, SCH: 111.6± 8.8%, p= 0.3, paired t-test, n= 6,
power: 0.07). Taken together, the results of these dopaminergic
modulators suggest that D3 receptor-mediated actions affect WT
andMeis1KO similarly, while activation of D1 receptor signaling
pathways exert similar effects in Meis1KO and D3KO but not
WTs.
D1R and D3R Protein Expression in the
Lumbar Spinal Cord of WT, Meis1KO, and
D3KO Animals
As treatments with D3- and D1 receptor-preferring agonists
and antagonists respectively led to different outcomes, we next
tested if the expression of these dopamine receptor subtypes
was differentially regulated in Meis1KO and D3KO over WT
(Figures 6, 7). We found that D3 receptor protein expression
did not significantly differ between WTMeis1, Meis1KO, and
D3KO (WT: 99.1± 3.5%; Meis1KO: 128.7± 8.5%; D3KO: 126.5
± 11.5%, p = 0.16, One-Way ANOVA; Figure 6). Note that
the D3KO expresses a dysfunctional D3 receptor that is not
embedded into the membrane (Clemens et al., 2005). In contrast
to the D3 receptor, when we probed for D1 receptor expression
in the spinal cord, we found significantly increased D1 receptor
protein levels in both Meis1KO and D3KO over WT controls
(WT: 99.9± 8.4%; Meis1KO: 158.4± 13.5%; D3KO: 162± 12%,
p= 0.003, One-Way ANOVA, Figure 7).
Increased Locomotor Activity in Meis1KO
And D3KO Animals
As the pharmacological and Western blot data suggested a role
of the D1 receptor system in the control of spinal cord function,
and as D1 receptor activation can recruit spinal cord networks
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FIGURE 2 | Thermal pain withdrawal latencies of WT, Meis1KO, and D3KO under sham (Ctrl) and morphine conditions. (A1) Normalized representation of data from
WTmeis1 animals. Morphine significantly increased withdrawal latencies. (A2) Normalized representation of data from the pooled Meis1KO animals. As in WTmeis1,
morphine significantly increased withdrawal latencies. (B1) Normalized representation of data from WTD3KO animals. Morphine significantly increased withdrawal
latencies. (B2) Normalized representation of data from D3KO animals. Unlike in both WT lines and Meis1KO, morphine had no effect on withdrawal latencies in D3KO.
to generate locomotor-like activities, we next tested if Meis1KO
andD3KO show altered locomotor activities over their respective
WT controls (Figure 8). We found that Meis1KO exhibited
significantly increased locomotor activities compared to their
WT (WTmeis1: 86.1 ± 13.7 m/day, n = 7; Meis1KO: 399.7 ±
35.5 m/day, n = 8, p < 0.001, t-test, power: 1.0), and that D3KO
showed a similar significant increase over their WT controls
(WTD3KO: 343.2.± 41.3 m/day, n= 16; D3KO: 587± 120m/day,
n= 8, p= 0.035, t-test, power: 0.48).
DISCUSSION
Here we compared thermal pain withdrawal latencies in two
animal models of RLS, D3KO, and Meis1KO mice against wild
type (WT) controls under different drug treatment conditions.
We found that, under baseline conditions (sham), withdrawal
latencies of WT and Meis1KO were similar, while those of
D3KO were decreased, suggesting heightened excitability in
these animals to a thermal stimulus and confirming earlier
in vivo and in vitro studies (Keeler et al., 2012). DA acts
via both excitatory (D1 and D5 receptor) and inhibitory (D2,
D3, and D4 receptor) receptor subtypes, and D3KO animals
express increased locomotor and rearing activities, indicating an
inhibitory role of the D3 receptor in the control of these motor
behaviors (Accili et al., 1996). Moreover, while present in all
laminae of the spinal cord (Zhu et al., 2007), the D3 receptor
is most densely expressed in the dorsal horn (Levant, 1998),
suggesting a strong modulatory effect of D3 receptor-mediated
pathways in this sensory area of the cord. Further, the lack of
function of the inhibitory D3 receptor in the isolated spinal
cord in vitro was sufficient to increase the number or large-
reflex spinal reflex amplitudes when compared to WT controls
(Clemens and Hochman, 2004). Similar to D3KO, Meis1KO
show a pattern of hyperactivity but contrary to D3KO, express
no significant nociceptive differences in a hotplate test (Salminen
et al., 2017). This is consistent with our findings under baseline
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FIGURE 3 | Thermal pain withdrawal latencies of WT, Meis1KO, and D3KO before and after D3 receptor agonist (PPX) treatment. (A1) Normalized representation of
data from WTmeis1 animals. PPX significantly increased withdrawal latencies. (A2) Normalized representation of data from the Meis1KO animals. As in WTmeis1, PPX
significantly increased withdrawal latencies. (B1) Normalized representation of data from WTD3KO animals. PPX significantly increased withdrawal latencies. (B2)
Normalized representation of data from D3KO animals. Unlike in both WT lines and Meis1KO, the D3 receptoer agonist PPX had no effect on withdrawal latencies in
D3KO.
FIGURE 4 | Thermal pain withdrawal latencies of Meis1KO and D3KO before and after treatment with the D3R antagonist SB 277011. (A) In Meis1KO, SB277
significantly decreased withdrawal latencies. (B) In D3KO, treatment with SB277 did not lead to any significant changes in withdrawal latencies.
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FIGURE 5 | Thermal pain withdrawal latencies of WT, Meis1KO, and D3KO before and after D1 receptor agonist (SKF) treatment. (A1) Normalized representation of
data from WTmeis1 animals. SKF did not have a significant effect on withdrawal latencies. (A2) Normalized representation of data from the Meis1KO animals. SKF
significantly increased withdrawal latencies. (B1) Normalized representation of data from WTD3KO animals. SKF did not significantly alter withdrawal latencies in
WTD3KO. (B2). Normalized representation of data from D3KO animals. As in Meis1KO, the D1 receptor agonist significantly decreased withdrawal latencies in D3KO.
conditions where Meis1KO and WT express similar withdrawal
thermal pain latencies, whereas reflex latencies are decreased in
D3KO (Figure 1).
Effects of Morphine
Opioids are powerful modulators of nociceptive pathways, and
we have shown previously that low morphine exposure (at
2 mg/kg, i.p.) was unsuccessful in modulating thermal pain
withdrawal reflexes in D3KO and that this effect could be
mimicked by acutely blocking D3 receptors in the isolated
WT spinal cord preparation (Brewer et al., 2014). There, we
also reported that the lack of a morphine effect in the D3KO
animal was associated with an increased expression of the
D1 receptor subtype in the spinal cord. While we did not
perform other behavioral tests on pain (i.e. von Frey testing for
mechanical pain), we confirmed the earlier D3KO findings here.
We also found that Meis1KO and WT respond to morphine
similarly (Figure 2). These data suggest that their opioid receptor
pathways are alike, and preliminary Western blots indicate that
the protein expression of the phosphorylated MOR is similar
between WT and Meis1KO, but significantly increased in D3KO
(data not shown). We are currently assessing if those receptor
changes are found systemwide in the CNS or whether they are
confined to specific (dorsal or ventral) areas of the spinal cord.
Effects of L-Dopa
We used L-DOPA (levodopa) as the immediate precursor of DA,
to test the effects of raised DA levels on sensorimotor function
in the three animal lines but observed no clear effect in either
animal line. While L-DOPA plays an important modulatory role
in controlling, at least temporarily, RLS symptoms (Akpinar,
1982; Paulus and Schomburg, 2006; Stiasny-Kolster et al., 2013),
it can exert differential effects on monosynaptic and oligo- or
polysynaptic nociceptive and non-nociceptive reflexes, where it
depresses monosynaptic reflexes of flexors but not extensors, but
also depresses transmission in nociceptive flexor reflex pathways
(Schomburg and Steffens, 1998). There are several not mutually
exclusive scenarios that may explain lack of any significant effect
in our experiments: i) we only tested L-DOPA at a single dose
of 10 mg/kg thus it is possible that lower or higher doses
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FIGURE 6 | D3R expression in the lumbar spinal cord. (A). Western blot of
D3R protein expression in the spinal cord. Top: D3R protein band; bottom:
protein loading control. (B). Quantification of D3R protein expression in the
spinal cord, normalized to protein loading control / lane. D3R expression was
not significantly altered in Meis1KO and D3KO animals. ∧: D3KO lanes that
were excluded from the subsequent analysis.
would have yielded different results. However, doses of less
than 10 mg/kg have been sufficient to provide behavioral effects
and induce L-DOPA-induced dyskinesia in 6-hydroxydopamine
lesioned mice (Lundblad et al., 2004). ii) Increasing dopamine
levels with L-DOPA does not necessarily target the different DA
receptor subtypes similarly. It is conceivable that high-affinity
D3 receptor-activated inhibitory pathways compete with low-
affinity D1 receptor-activated excitatory pathways, resulting in a
net zero effect of this drug. iii), L-DOPA may act on the different
components of sensory pain pathways differently; for example, in
high spinal cats the onset of reflex facilitation induced by noxious
radiant heat and mediated by A∂ fibers is delayed after injection
of L-DOPA, while the late component persisted (Schomburg
et al., 2011).
Effects of D3R and D1R Agonists and
Antagonists
While the conversion of L-DOPA to DA can lead to an
activation of both inhibitory and excitatory receptor subtypes,
we hypothesize that our findings reflect a strong influence of
the D3 receptor in mediating the behavioral responses tested.
The D3 receptor has a very high affinity to DA (Cote and
Kuzhikandathil, 2014), thus an initial DA increase will primarily
(but not exclusively) mediate an inhibitory response that should
be missing in the D3KO. Both D3 and D1 receptors are expressed
in the lumbar spinal cord (Zhu et al., 2007), and DA can
FIGURE 7 | D1R expression in the lumbar spinal cord. (A) Western blot of
D1R protein expression in the spinal cord. Top: D1R protein band; bottom:
protein loading control. (B) Quantification of D1R protein expression in the
spinal cord, normalized to protein loading control / lane. D1R expression was
significantly increased in Meis1KO and D3KO over WT animals.
FIGURE 8 | Spontaneous locomotor activities of Meis1KO and D3KO and
their respective controls. (A) Meis1KO. Meis1KO displayed significantly
increased locomotor activities per 24 h over their WT controls (WTMeis1). (B)
Similar to Meis1KO, D3KO animals ran significantly longer distances per day
over their controls (WTD3KO).
up- or downregulate cellular and network functions in a dose-
dependent manner (Missale et al., 1998; Thirumalai and Cline,
2008; Clemens et al., 2012). Current DA-based RLS treatment
options center aroundD3 receptor agonists (Ferini-Strambi et al.,
2016; Ferré et al., 2017), but their effect is reduced over time
and can cause a worsening of the symptoms (augmentation)
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(Allen et al., 2011; García-Borreguero and Williams, 2011;
Earley et al., 2017; Trenkwalder et al., 2017). While we have
previously shown that D3 receptor agonists and antagonists
can oppositely regulate spinal reflex amplitudes (SRAs) of WT
in vitro while they do not alter SRAs in D3KO (Clemens
and Hochman, 2004), we here wanted to test how these
neuromodulators act in vivo, and how their effects compare
with the Meis1KO animals (Figure 4). Treatment with both D3
receptor modulators (agonist pramipexole; PPX, and antagonist
SB277011-A; SB277) led to nearly identical outcomes in WT and
Meis1KO respectively, and had, as expected, no effect in the
D3KO. In WT and Meis1KO, PPX had a strong analgesic effect
that was counteracted by SB277, suggesting a similar role for
the D3 receptor in modulating the thermal nociceptive pathway
in these two animal strains. As the D3 receptor in the spinal
cord is most prominently expressed in the sensory neurons of
the dorsal horn (Levant, 1998), it is tempting to speculate that
reduced DA levels at this sensory interface in the evening or at
night (Carlsson et al., 1980; Sowers and Vlachakis, 1984) might
reduce descending inhibitory control and thus contribute to the
emergence of the circadian symptoms in RLS (“urge to move”).
Of particular note is that such a reduced functional state of the
D3 receptor in the dorsal horn could also arise independent of
circadian DA levels, either by Meis1-dependent compromised
projections of descending DA fibers from the A11 nucleus (M.
Aschner, personal communication) or with the normal aging-
related gradual decline of DA levels (Haycock et al., 2003) and
a subsequent reduction in the expression levels of inhibitory Gi-
coupled DA receptors (Mesco et al., 1991; Valerio et al., 1994).
As with the circadian DA fluctuations, low DA levels would first
affect the D3R and thus reduce overall DA-mediated inhibition.
The D3KO animal then could serve as a model to specifically
assess the mechanisms that follow a D3 receptor dysfunction in
the sensory part of the spinal cord.
In contrast to D3 receptor modulators, the effects of the D1
receptor agonist was similar between Meis1KO and D3KO, but
had no effect in WT. We suspect that the increase in spinal
D1R protein expression (discussed below)may be the component
that drives this behavioral outcome. We here confirmed that
both Meis1KO and D3KO animals express increased locomotor
activities (Accili et al., 1996; Salminen et al., 2017), and there
is ample evidence that, in the isolated spinal cord preparation,
D1R agonists can activate the central pattern generator (CPG)
for locomotion (Kiehn and Kjaerulff, 1996) (Starr and Starr,
1993; Lapointe and Guertin, 2008; Urs et al., 2011; Sharples
et al., 2015). As the locomotor CPG is contained to the ventral
aspect of the thoraco-lumbar spinal cord (Kjaerulff and Kiehn,
1996; Kiehn, 2006, 2016) and the D1 receptor is more strongly
expressed in ventral than sensory areas of the spinal cord (Zhu
et al., 2007), D1 receptor-mediated actions may predominantly
target motor-related over sensory functions in the spinal cord.
Intriguingly, periodic limb movements during sleep (PLMS) are
often associated with RLS (Wetter and Pollmächer, 1997; Moore
et al., 2014; Li et al., 2016), and PLMS scores are regularly used
to quantify RLS severity (Happe et al., 2001; Manconi et al.,
2011b; Winkelmann et al., 2017). The similar responsiveness of
Meis1KO and the D3KO to the D1 receptor modulators and
their heightened motor activity suggest that the excitability of the
spinal CPG may be upregulated in these animals, possibly via a
D1 receptor-dependent beta-arrestin 2/phospho-ERK signaling
complex that selectively mediates the locomotor CPG (Urs et al.,
2011), which then could provide a target to understand the
development of PLMS in future mechanistic studies.
D3R and D1R Protein Expression in the
Spinal Cord
All DA receptor-mRNAs are expressed in the neurons of the
rodent spinal cord (Zhu et al., 2007), although it is unclear if
this translates also to proteins similarly, and if it is also the
case in primates and man. For example, in non-human primates
the D1 receptor is missing in the cord (Barraud et al., 2010),
however its functionsmay be compensated for by the D5 receptor
subtype, which also activates adenylyl cyclase (Missale et al.,
1998). Using standard Western blot techniques, we tested for D3
receptor and D1 receptor protein expression in the lumbar spinal
cord of the three animal models tested behaviorally. While we
found no significant difference in D3 receptor expression across
WT, Meis1KO and D3KO (Figure 6), we observed a significant
upregulation of D1 receptor protein expression in Meis1KO and
D3KO over WT (Figure 7). While present at relatively low levels
in the spinal cord (Zhu et al., 2007), quantitative autoradiography
has revealed that the D3 receptor is predominantly expressed in
the dorsal horn (Levant, 1998), where it is in a prime position to
modulate sensory pathways. In contrast, D1 receptor activation
is regularly used to induce fictive locomotion in the isolated
spinal cord preparation (Lapointe and Guertin, 2008; Han and
Whelan, 2009; Sharples et al., 2015), suggesting a strong influence
of the D1 receptor system to activate these more ventrally located
circuits. Thus an increase in the availability or activation of
D1 receptors in D3KO animals could explain an increase in an
overall increase in the overall excitability and activity, similar to
that observed with normal aging (Keeler et al., 2016).
The presence of a D3 receptor protein in the D3KO may
appear unexpected, but the D3KO mouse used in our studies is
not a genetic knockout of the D3 receptor; rather it is a targeted
mutation of the D3 receptor gene in the second intracellular loop
of the predicted protein sequence that prevents the incorporation
of the D3R into the membrane (Accili et al., 1996). While this
mutation does not preclude the transcription and translation of
the D3 receptor, it prevents its insertion into the cell membrane
(Zhu et al., 2008), rendering it functionally inactive (Clemens
and Hochman, 2004). The lack of a difference between WT
and Meis1KO supports the behavioral effects of the D3 receptor
compounds and underlines the similarities between these two
models with regard to the modulation of their sensory circuits.
In contrast to the D3 receptor data, the results of the D1
receptor protein expression point to a similarity of Meis1KO and
D3KO, but not with either of them and the WT. We have shown
previously that D3KO express not only decreased thermal pain
withdrawal latencies but also an increased spinal D1 receptor
protein expression (Brewer et al., 2014), and it is possible that
in these animals a lack of synergistic D1-D3 receptor intra-
membrane receptor-receptor interactions may account for the
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underlying mechanism that is responsible for this behavioral
outcome (Marcellino et al., 2008). However, our data do not
completely answer the question if there is a spatial component
to the differences in D3 receptor and D1 receptor protein
expression in the cord between the two genetically-modified
animals and theirWT controls.While we performed ourWestern
blot experiments on lumbar spinal segments only, we did not
anticipate the outcome that point to potential differential changes
in sensory and motor circuits, and hence did not further dissect
out and differentiate the outcomes between ventral versus dorsal
aspects within those segments.
The Caveat of Using Dopaminergics in vivo
to Test Sensorimotor Circuits in the Spinal
Cord
Descending DA projections to and the presence of DA receptors
in the spinal cord are well established (Holstege et al., 1996;
van Dijken et al., 1996; Levant, 1998; Zhu et al., 2007), yet
we cannot exclude the possibility that any of the drugs tested
may have triggered changes in descending pathways, which in
turn altered spinal reflex circuit excitabilities. Possible alternate
approaches to test whether the DA effects are systemwide or
truly spinal, which was beyond the scope of this study, would
be to test the modulatory effects of these compounds in acutely
anesthetized and spinalized animals, or by employing intrathecal
drug delivery or conditional knockout approaches. In fact, data
from a preliminary study, in which a D3 receptor-specific blocker
was applied intrathecally, indicate that such an intrathecal
approach alone can alter locomotor patterns and spinal D1
receptor expression (Jensen et al., 2014).
D3KO and Meis1KO–Complementary
Models of RLS?
Figure 9 presents a comparative model, in which we summarize
baseline properties, behavioral responses to the drugs tested,
and D1 and D3 receptor protein expression data between WT,
Meis1KO, and D3KO. WT and Meis1KO are similar with
regard to sensory excitability at baseline (sham), their behavioral
responses to morphine and D3 receptor modulators, and the
expression levels of the spinal D3 receptor. Importantly, WT are
different from D3KO with regard to baseline, opioid response,
D1 receptor modulators, and D1 receptor expression. While
Meis1KO and D3KO differ from each other in baseline and
opioid response, they react similarly to D1 receptor modulators,
and they express similarly increased D1 receptor protein
expression levels in the lumbar spinal cord. As Meis1KO show at
baseline only an increased locomotor activity, but normal sensory
excitability, and as locomotor circuits are located in the ventral
FIGURE 9 | Model of relationships between WT, Meis1KO, and D3KO animals. WT and Meis1KO share a similar baseline under control conditions, respond similarly
to opioids, and have a similar D3R expression in the spinal cord. However, they differ in their responses to D1R modulators. WT and D3KO have different baselines
under control conditions and respond differently to opioids, D3R, and D1R modulators. Meis1KO and D3KO have different baselines under control conditions, but
respond similarly to D1R modulators, and have similar D1R expression levels in the spinal cord.
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horn of the spinal cord, we posit that the Meis1KO mouse may
serve as a model to specifically explore the mechanisms affiliated
with themotor-related aspects of RLS (i.e. PLMS). In contrast, the
increased sensory excitability and locomotor activity in D3KO
suggest that both sensory and motor circuits are functionally
upregulated in the spinal cord of this mouse, and that this model
may be used to examine the impact of both sensory and motor
pathways affiliated with RLS.
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